Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RUSHANG D PATEL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1891956892
CMS profile
40258
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$99,597.69

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Kite Pharma, Inc. $28,028.15 28
PFIZER INC. $27,395.82 14
Adaptive Biotechnologies Corporation $20,767.52 7
Genmab U.S., Inc. $19,549.19 15
Janssen Biotech, Inc. $2,489.26 3
ABBVIE INC. $850.00 1
Daiichi Sankyo Inc. $133.00 1
Astellas Pharma US Inc $99.95 1
Incyte Corporation $87.99 1
Celgene Corporation $59.75 3
Ambu Inc. $55.55 1
Legend Biotech USA Inc. $43.31 1
GENZYME CORPORATION $19.88 1
Novartis Pharmaceuticals Corporation $18.32 1

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RUSHANG D PATEL

NPI 1891956892 · CMS profile ID 40258

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891956892?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RUSHANG D PATEL, NPI 1891956892, CMS profile ID 40258. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891956892?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RUSHANG D PATEL, NPI 1891956892, CMS profile ID 40258. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891956892?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RUSHANG D PATEL, NPI 1891956892, CMS profile ID 40258, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1891956892?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $99,597.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kite Pharma, Inc. $48.3805/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610229 CMS
Kite Pharma, Inc. $70.0005/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610231 CMS
Kite Pharma, Inc. $40.1605/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610233 CMS
Kite Pharma, Inc. $182.7705/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610235 CMS
Kite Pharma, Inc. $33.5005/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610241 CMS
Kite Pharma, Inc. $559.2005/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610243 CMS
Kite Pharma, Inc. $30.2005/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610245 CMS
Kite Pharma, Inc. $24.1805/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610247 CMS
Kite Pharma, Inc. $40.7805/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610239 CMS
Kite Pharma, Inc. $15.1405/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610249 CMS
PFIZER INC. $1,575.0005/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131483350 CMS
Daiichi Sankyo Inc. $133.0005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089467398 CMS
Novartis Pharmaceuticals Corporation $18.3204/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087290269 CMS
PFIZER INC. $9,800.0004/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131482292 CMS
PFIZER INC. $411.2004/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131483359 CMS
PFIZER INC. $566.0204/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131483371 CMS
GENZYME CORPORATION $19.8804/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139855261 CMS
Adaptive Biotechnologies Corporation $3,850.0004/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150259660 CMS
Adaptive Biotechnologies Corporation $117.5204/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150264049 CMS
ABBVIE INC. $850.0004/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105200520 CMS
Incyte Corporation $87.9904/08/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141227730 CMS
Genmab U.S., Inc. $77.1404/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126831540 CMS
Kite Pharma, Inc. $27.6803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610251 CMS
Adaptive Biotechnologies Corporation $3,850.0003/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150259664 CMS
Astellas Pharma US Inc $99.9503/01/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139345344 CMS
PFIZER INC. $112.0001/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131483363 CMS
PFIZER INC. $2,800.0001/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131483367 CMS
Adaptive Biotechnologies Corporation $3,850.0001/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150259662 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,503.71 40
PY2020 $99.00 1
PY2021 $1,718.86 7
PY2022 $5,255.43 22
PY2023 $64,973.96 69
PY2024 $99,597.69 78
PY2025 $186,620.63 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $106,070.02 32
PY2024 Principal investigator $349,643.12 28
PY2023 Principal investigator $19,664.40 4
PY2022 Principal investigator $46,788.22 5
PY2021 Principal investigator $50,485.57 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,486.00 12/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175391503
Principal investigator 1 Janssen Research & Development, LLC $131.00 12/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175391666
Principal investigator 1 Janssen Research & Development, LLC $3,730.80 11/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175391826
Principal investigator 1 Janssen Research & Development, LLC $5,475.00 11/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175391353
Principal investigator 1 Janssen Research & Development, LLC $1,989.00 10/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175391671
Principal investigator 1 Janssen Research & Development, LLC $466.00 09/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391487
Principal investigator 1 Janssen Research & Development, LLC $2,089.80 09/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391753
Principal investigator 1 Janssen Research & Development, LLC $5,694.00 09/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391776
Principal investigator 1 Janssen Research & Development, LLC $1,474.00 08/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391693
Principal investigator 1 Janssen Research & Development, LLC $190.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391363
Principal investigator 1 Janssen Research & Development, LLC $3,486.00 07/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391436
Principal investigator 1 Janssen Research & Development, LLC $9,396.00 07/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391464
Principal investigator 1 Janssen Research & Development, LLC $10,378.00 07/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391619
Principal investigator 1 Janssen Research & Development, LLC $1,284.00 07/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391759
Principal investigator 1 Janssen Research & Development, LLC $1,989.00 07/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391687
Principal investigator 1 Janssen Research & Development, LLC $201.00 06/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391819
Principal investigator 1 Janssen Research & Development, LLC $1,284.00 06/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391796
Principal investigator 1 Janssen Research & Development, LLC $6,793.00 06/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391476
Principal investigator 1 Janssen Research & Development, LLC $7,218.00 06/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391493
Principal investigator 1 ABBVIE INC. $2,756.70 05/06/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202403474
Principal investigator 1 Janssen Research & Development, LLC $3,606.00 05/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391614
Principal investigator 1 Janssen Research & Development, LLC $3,620.00 03/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391527
Principal investigator 1 Janssen Research & Development, LLC $466.00 03/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,801.36 03/04/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1223263392
Principal investigator 1 Janssen Research & Development, LLC $1,064.01 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391561
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 02/11/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1223263386
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 02/11/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1223263388
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 02/11/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1223263390
Principal investigator 1 Janssen Research & Development, LLC $5,210.00 02/10/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $944.06 02/03/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1223263384
Principal investigator 1 Janssen Research & Development, LLC $571.00 01/27/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) No dispute reported 06/30/2026 1175391381
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,826.29 01/21/2025 Non-covered Recipient Entity
Adventhealth
Randomized, open-label, Phase 3 trial to evaluate efficacy and safety of ide-cel with lenalidomide maintenance (Arm A) versus lenalidomide maintenance therapy (Arm B) in adult NDMM patients with suboptimal response after ASCT. No dispute reported 06/30/2026 1235999213